Results 121 to 130 of about 1,054,375 (301)

Recurrent urothelial tumors following surgery for transitional cell carcinoma of the upper urinary tract

Cancer, 1976
D. Strong, H. D. Pearse
semanticscholar   +1 more source

PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma

Advanced Science, EarlyView.
Integrated scRNA‐seq, scTCR‐seq analysis, and functional assays identify PRDM1+ malignant epithelial cells with hyper lipid peroxidation characteristics that demonstrate reduced responsiveness to the nICRT treatment. Principal factor PRDM1 activates cysteine metabolism genes to modulate lipid peroxidation (an intrinsic cellular pathway related to ...
Dijian Shen, Rui Li, Yong She, Xuefei Liu, Yuanyang Huang, Yongling Ji, Keying Chen, Zhengbo Song, Runzhe Chen, Xuan Li, Qi Zhao, Qixun Chen, Ming Chen   +12 more
wiley   +1 more source

Transitional cell carcinoma in untreated adult bladder exstrophy: A rare case report. [PDF]

Urol Case Rep, 2022
Handoko RR, Ismy J, Badiri I.
europepmc   +1 more source

Phase Separation of NFIB Suppresses SLC3A2‐Mediated Ferroptosis in Castration‐Resistant Prostate Cancer

Advanced Science, EarlyView.
Castration‐resistant prostate cancer (CRPC) remains sensitive to ferroptosis, but its intrinsic resistance is poorly understood. Here, we identify NFIB as a master suppressor. SIRT7‐mediated NFIB acetylation drives its liquid–liquid phase separation, which promotes SLC3A2 transcription to inhibit ferroptosis.
Qiunuo Li, Danyang Chen, Yongzhen Xia, Yili Long, Nan Huang, Rongna Li, Mengting Shi, Mairehaba Kadier, Huafeng Luo, Xiaohui Chen, Hao Liu, Guanmin Jiang   +11 more
wiley   +1 more source

Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507). [PDF]

BMC Urol, 2023
Tempo J, Bolton D, O'Callaghan M.
europepmc   +1 more source

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.

New England Journal of Medicine, 1991
D. Lamm, B. Blumenstein, E. Crawford, J. Montie, P. Scardino, H. Grossman, T. Stanisic, Joseph A. Smith, Jerry Sullivan, M. Sarosdy, J. Crissman, C. Coltman   +11 more
semanticscholar   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Identification of Biomarkers Related to Prognosis of Bladder Transitional Cell Carcinoma. [PDF]

Front Genet, 2021
Liu Z, Xu L, Lin Y, Hong H, Wei Y, Ye L, Wu X.   +6 more
europepmc   +1 more source

Transitional cell carcinoma of the prostate. A clinical morphological study

Cancer, 1972
Douglas E. Johnson, J. Hogan, A. Ayala
semanticscholar   +1 more source

pH/ROS‐Responsive Injectable Hydrogel Co‐Loaded with B7‐H3 Blocker and NETs Suppressor Boosts OSCC Synergistic Immunotherapy

Advanced Science, EarlyView.
A pH/ROS‐dual‐responsive injectable hydrogel, formed by dynamic boronic ester and Schiff base crosslinking, co‐delivers enoblituzumab (B7‐H3 blocker) and Cl‐amidine (NETs suppressor). Via localized intratumoral delivery, it synergistically reprograms the immunosuppressive tumor microenvironment, overcomes T cell infiltration barriers, restores ...
Huan Li, Yun Li, Yating Hu, Yanbing Yao, Yaodong He, Jing Li, Jiaqi Tang, Zhenyan Zhao, Yan Wang, Yulun He, Xiaolong Zhang, Xinjie Yang, Jianhua Wei   +12 more
wiley   +1 more source